Use of adenosine A3 receptor antagonists to inhibit tumor growth
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Dec 4, 2001
Grant Date -
N/A
app pub date -
Aug 19, 1999
filing date -
Aug 25, 1998
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
Tumor growth and metastasis can be inhibited by administration of adenosine A.sub.1 and/or A.sub.3 antagonists, preferably A.sub.3 antagonists, to a patient. The antagonists can be, and preferably are, administered in combination with other anti-tumor agents, such as anti-angiogenic agents (including adenosine A.sub.2a antagonists) and/or cytotoxic agents. Because the cytotoxic agents attack the tumor cells themselves, and the anti-angiogenic agents prevent the growth of vasculature which would otherwise support the growth of the tumor cells.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully